Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of MRG-110 Following Local Intradermal Injection After Skin Excisional Wound Creation in Normal Healthy Volunteers

Next Previous
Search
Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of MRG-110 Following Local Intradermal Injection After Skin Excisional Wound Creation in Normal Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRG-110 (Primary)
  • Indications Wounds
  • Focus Adverse reactions
  • Sponsors miRagen Therapeutics; Viridian Therapeutics

Most Recent Events

  • 16 Oct 2019 According to a miRagen Therapeutics media release, data of this trial will be included in an oral presentation detailing the MRG-110 program provided by Dr. Rusty L. Montgomery, Director of Research, miRagen Therapeutics, today at the 15th annual meeting of the Oligonucleotide Therapeutics Society, which is being held in Munich, Germany.The presentation will be available on the scientific publications page of the Companys website following the presentation.
  • 16 Oct 2019 Results presented in a miRagen Therapeutics Media Release.
  • 03 May 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top